Tasigna (nilotinib) / Novartis, Inhibikase  >>  Phase 1
Welcome,         Profile    Billing    Logout  

6 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tasigna (nilotinib) / Novartis, Inhibikase
ChiCTR-ONC-10000894: Nilotinib plus multi-agent chemotherapy for philadelphia chromosome-positive acute lymphoblastic leukemia

Recruiting
1
30
 
Nilotinib plus multi-agent chemotherapy
Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences; Novartis pharmaceutical co., Ltd, Novartis pharmaceutical co., Ltd
Philadelphia chromosome-positive acute lymphoblastic leukemia
 
 
NCT01407198: Nilotinib With Radiation for High Risk Chordoma

Active, not recruiting
1
29
US
Nilotinib, AMN 107, Tasigna, Radiation therapy, External beam radiation
Massachusetts General Hospital
Chordoma
02/16
12/25
CABL001X2101, NCT02081378: A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Completed
1
326
Europe, Japan, US, RoW
Asciminib (ABL001), ABL001, Nilotinib, Imatinib, Dasatinib
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
06/21
03/23
NCI-ALMANAC, NCT02379416: Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors

Recruiting
1
70
US
Nilotinib + Paclitaxel
National Cancer Institute (NCI)
Solid Tumors
12/24
12/24
NCT04205903: Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer

Recruiting
1
20
US
Nilotinib, AMN 107 Base Form, Nilotinib Hydrochloride Monohydrate, AMN107, Nilotinib Monohydrochloride Monohydrate, Tasigna, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Placebo, placebo therapy, PLCB, sham therapy, Questionnaire Administration
Ohio State University Comprehensive Cancer Center, National Cancer Institute (NCI)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
01/24
01/24
NCT04903119: Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma

Recruiting
1
15
US
Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg, Nilotinib 400mg, Dabrafenib, Trametinib
Jill M Kolesar, Novartis, National Cancer Institute (NCI)
Metastatic Melanoma, BRAF Gene Mutation
12/26
03/27

Download Options